How Much Is A Microdose?
- Anahita Anais
- Jun 28, 2021
- 9 min read
Updated: 5 days ago
Last updated: June 2026.
This article is educational and is not medical advice. Psilocybin and LSD are Schedule I substances; talk with your doctor before making any health decision.
A microdose is a small amount of a psychedelic, low enough that you do not feel high, drift, or hallucinate. The point of a microdose is to stay fully functional while taking a fraction of a recreational dose. So the honest answer to "how much" is: much less than most people expect, measured in different units depending on the substance, and never a fixed number you should copy from a stranger online.
This article is educational, not medical advice. Both psilocybin and LSD are Schedule I substances under the U.S. Controlled Substances Act, which means making, possessing, or selling them is a federal crime regardless of state reform (DEA / Controlled Substances Act overview). Know your local law, and know that nothing below is a prescription.
Read The Units First
The single most dangerous mistake in microdosing is confusing units. Get this wrong, and you can turn an imperceptible dose into an overwhelming one.
LSD is measured in micrograms (µg / mcg), millionths of a gram. A microdose is roughly 5–20 micrograms. Never milligrams. A milligram figure for LSD is a thousand times too high and is not a microdose by any definition.
Dried psilocybin mushrooms are measured in grams of dried material. A microdose of dried Psilocybe cubensis is roughly 0.05–0.30 g (50–300 mg). This is the weight of the dried mushroom, not pure psilocybin, and potency varies widely by species, batch, and even the part of the mushroom.
If you only remember one thing from this page, remember that LSD lives in micrograms and mushrooms live in grams of dried material. They are not interchangeable scales. If you are new to the terms, it helps to first read the basics of microdosing technique before you think about any number at all.
The Research
The "one-tenth" rule. The most common way people estimate a microdose is to take roughly one-tenth to one-twentieth of a full recreational dose. This heuristic was popularized in James Fadiman's early observational work, which described a microdose in the range of about 10 micrograms of LSD taken every few days (Fadiman & Korb, Journal of Psychoactive Drugs, 2019). It is a starting estimate, not a precise standard, and it does not translate cleanly across substances of different potency.
What people report. In a study of 278 microdosers, the most commonly reported benefits were improved mood (about 27%) and improved focus (about 15%), alongside self-reported reductions in caffeine, alcohol, and other substance use (Anderson et al., Harm Reduction Journal, 2019). A separate observational study found small-to-medium self-reported improvements in mood and mental health over about 30 days compared with non-microdosing controls (Rootman et al., Scientific Reports, 2022). These are early, self-reported, observational findings, not proof of effect.
The placebo problem. When microdosing has been tested under controlled conditions, the picture gets more cautious. The largest placebo-controlled microdosing study to date used a clever "self-blinding" design with 191 participants and found that the psychological benefits people reported could be explained largely by the placebo effect (Szigeti et al., eLife, 2021). A preregistered, placebo-controlled field-and-lab study likewise found that psilocybin microdosing did not measurably change emotion-related symptoms (Marschall et al., Journal of Psychopharmacology, 2022). Honest reading: people consistently report feeling better, and controlled trials have so far struggled to confirm that the dose itself, rather than expectation, is doing the work.
What's changed since then (2024–2025). Two developments are worth knowing if you last read about this a few years ago. First, a 2024 rapid review by Vince Polito and Paul Liknaitzky pushed back on the "it's all placebo" conclusion. They did not claim microdosing works; they argued that the controlled studies so far are too small, too short, and too narrow (mostly healthy volunteers, few doses) to settle the question either way. Their verdict is that the placebo-versus-real debate is currently inconclusive (Polito & Liknaitzky, Journal of Psychopharmacology, 2024). Second, newer controlled work has kept pointing the same direction as the earlier negative trials: results from two double-blind, placebo-controlled longitudinal trials published in 2025 did not find that psilocybin microdosing reliably improved cognition or emotional functioning beyond placebo (Murphy et al., Neuropsychologia, 2025). The state of the evidence in 2026 is the same shape as before, just better documented: real-world reports stay positive, controlled trials stay underwhelming, and serious researchers disagree about why.
A note on the legal climate. Microdosing has not moved closer to legal medical access. In August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, the application closest to bringing a psychedelic into mainstream medicine, citing trial-design and blinding problems, and that decision and its reasoning were made public in 2025 (NPR, 2024). For the substances in this article, the practical bottom line is simpler: psilocybin and LSD remain Schedule I, no doctor can prescribe them, and the recent expansions in telehealth prescribing of controlled substances apply only to Schedules II through V, not to anything discussed here.
Pain is a narrower, more controlled signal. One area with cleaner experimental data is acute pain perception. In a randomized, placebo-controlled study, healthy volunteers given single LSD doses of 5, 10, and 20 micrograms could tolerate a cold-water pain task longer at 20 micrograms, with no significant effect at 5 micrograms and a borderline effect at 10 (Ramaekers et al., Journal of Psychopharmacology, 2021). This was experimental, acute pain in healthy people. It is early evidence about pain perception, not evidence that microdosing treats chronic pain conditions, and it should not be read that way.
The takeaway across all of this: early research may suggest benefits for mood and possibly pain perception, but the evidence is mixed, much of it is self-reported, and the placebo effect is a serious confounder. Anyone telling you the science is settled is overselling it.
Species, Strains, And Potency: Why A Gram Is Not A Gram
The 0.05 to 0.30 g range above assumes dried Psilocybe cubensis, the species almost everyone grows, and the reference this guide uses. Potency varies at three levels: species, strain, and even batch. This is exactly where weight-based dosing goes wrong.
Across species. Psilocybin content varies several-fold. Cubensis sits in the lower-to-middle range, around 0.6 to 1.0% by dry weight. Some wild species are far stronger. Psilocybe azurescens can reach roughly 1.8%, and Psilocybe semilanceata (liberty caps) and Panaeolus cyanescens run high too. The most potent carry roughly 2 to 3 times more psilocybin per gram than cubensis (ICEERS). So a 0.1 g microdose of cubensis is not the same as 0.1 g of azurescens; by weight, the second could be two or three times the dose.
Within cubensis, strains differ too. Golden Teacher is the mild, beginner-friendly "gateway" strain. Penis Envy is reputed to be among the strongest, and often tests notably higher, by some accounts, roughly double Golden Teacher. That said, the lab picture complicates the legend: strain name is an unreliable predictor of potency, and how a mushroom is grown, its genetics, and how it is dried and stored matter as much as the strain itself (strain analysis). The practical point holds: a gram of Golden Teacher and a gram of Penis Envy are not interchangeable.
Even within one batch, potency swings. Researchers measured roughly a 40-fold difference between the weakest and strongest cubensis material (Journal of Pharmaceutical and Biomedical Analysis, 2024), and lookalike species are easy to misidentify, sometimes dangerously (DNA authentication of Psilocybe, 2022).
Amanita muscaria is a different mushroom entirely, and none of this applies to it. The red-and-white "fly agaric" is not a psilocybin mushroom. Its active compounds are ibotenic acid and muscimol, which act on GABA receptors, not serotonin: a different mechanism, different (often sedating, dream-like) effects, and a different risk profile, including ibotenic acid's neurotoxicity when the mushroom is not properly prepared (Amanita muscaria review, 2026). It is increasingly sold as a "legal microdose," but it must never be dosed by the psilocybin guidance here, and controlled human data on it is scarce.
The takeaway: this guide's range is calibrated for cubensis. Know your species and strain, treat every new batch as an unknown, start lower than you think, and remember that Amanita is a separate conversation with separate rules.
What I've Seen In My Work
The following are observations from my own practice, not clinical evidence.
In my work with people using dried Psilocybe cubensis, I rarely see a reason to go above roughly 0.09 g (90 mg) of dried material for a microdose, and I more often see people do well below that, sometimes below even a twentieth of a full dose. Optimal amounts are individual. This is professional judgment about a range, not a number you should apply to yourself, and it is not medical advice.
A few patterns I notice repeatedly:
More is not better. When someone feels anxious, wired, or distracted on a microdose, the answer is almost always less, not more. A dose you can feel is, by definition, past the microdose range.
Potency is the wildcard in practice. Beyond the species and batch differences above, I treat every new batch as an unknown until verified in a controlled dosing session. I have found products manufactured using psilocybin extracts to be more reliable in dose consistency than capsules, fruiting bodies, or products developed using mushroom powder.
Body, baseline, and other substances matter. One of the least understood factors in dose variability is the individual neurochemistry, which can fluctuate through a variety of factors like use of other substances (some even weeks prior), diet, sleep, nervous system state, health conditions, as well as herbal and pharmaceutical medications.
I share these as observations, not as a protocol to copy. The number that is right for one person can be wrong for another. People who want to support their nervous system around a microdose, sometimes pair it with non-psychedelic functional mushrooms; if that interests you, these three functional mushrooms and the well-known Stamets Stack are the usual starting points.
Start Low, Go Slow
If you are going to do this despite the legal and health risks, harm reduction means erring toward too little:
Begin at the bottom of the range and only adjust after several spaced doses, not within a single day.
Use an accurate scale. Dried mushroom microdoses are in the tens of milligrams, which a standard kitchen scale cannot read. A milligram scale (readable to 0.001 g) is the minimum for any honesty about your dose.
Test your substance. Misidentified mushrooms and adulterated or mislabeled LSD analogues are a genuine danger. Unknown research chemicals sold as "LSD" can be far more potent or toxic, and reagent testing is a basic safety step.
Do not combine with alcohol or other drugs while you are learning your response, and do not microdose and drive or operate machinery until you know how a given amount affects you.
Mind the interactions and the contraindications. A personal or family history of psychosis is a serious reason for caution, and several medications interact with psychedelics. This is a conversation for a qualified medical professional, not a blog.
If you are still weighing whether to do this at all, it is worth reading honestly about when microdosing can be dangerous before you settle on any amount.
Microdosing sits inside a much larger conversation about integrative medicine and nervous-system regulation: whether a small, intentional input can support a system that is already overloaded. That conversation is worth having seriously, which is exactly why the dose deserves to be treated with respect rather than guesswork.
Frequently Asked Questions
What Is The Most Common Microdose Amount?
For dried Psilocybe cubensis, people most often land somewhere in the 0.05 to 0.30 g range, and many do well at the lower end, around 0.05 to 0.10 g. For LSD, the usual range is 5 to 20 micrograms. These are ranges, not targets. The right amount for any one person is found by starting at the bottom and adjusting slowly, not by copying a number.
How Do I Know If My Dose Is Too High?
If you can feel it (visual changes, a noticeable shift in mood or energy, anxiety, restlessness, or anything that interferes with ordinary functioning), it is no longer a microdose. The defining feature of a microdose is that it is sub-perceptual. Feeling something is the signal to go lower, not higher.
Why Can't I Just Copy Someone Else's Dose?
Two reasons. First, individual response varies with body, baseline, and other substances. Second, potency itself varies enormously: lab analysis of Psilocybe cubensis has found around a 40-fold difference in psilocybin content between samples, so the same weight of two different batches can be wildly different doses. A number that worked for someone else, with their material, tells you little about yours.
Does The Research Show Microdosing Actually Works?
The honest answer is that it is unsettled. Real-world surveys consistently report better mood and focus, but the strongest controlled trials, including the largest self-blinding study, have struggled to separate those benefits from the placebo effect. A 2024 review argued the question is still genuinely open because the controlled studies are small and short. Treat anyone claiming certainty in either direction with skepticism.
Is Microdosing Legal?
In most of the United States, no. Psilocybin and LSD are Schedule I substances under federal law, and no doctor can prescribe them. A few states and cities have changed their local approach, but federal law still applies, and the recent FDA and telehealth developments have not changed the status of these substances. Know your local law.
Do I Need A Special Scale?
Yes, if you are dosing dried mushrooms. Microdoses are in the tens of milligrams, below the resolution of a kitchen scale. A milligram scale that reads to 0.001 g is the minimum for knowing your dose with any accuracy.
Skip The Guesswork
Microdosing should not be guesswork. If you want a clear, conservative starting framework that puts units, ranges, scheduling, and the harm-reduction basics in one place, the Microdose Guru Protocol Guide lays it out without the hype. Prefer to start smaller? The free mini-guide covers the essentials.
This article is for education only and is not medical advice. Psilocybin and LSD are Schedule I controlled substances under U.S. federal law. Nothing here is a recommendation to obtain or use an illegal substance.
